Showing results (2861-2870 of 6,517) with videos related to
Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|August 16, 2019
Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cellsStefanie Koristka, Pauline Ziller-Walter, Ralf Bergmann, et al.Cancer Immunology, Immunotherapy : CII|August 19, 2019
Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors aloneDavid Rafei-Shamsabadi, Saskia Lehr, Dagmar von Bubnoff, et al.Cancer Immunology, Immunotherapy : CII|August 25, 2019
Melanoma-conditioned medium promotes cytotoxic immune responses by murine bone marrow-derived monocytes despite their expression of 'M2' markersLiam Friel Tremble, Anne C Moore, Patrick F FordeCancer Immunology, Immunotherapy : CII|July 24, 2019
CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitroSandra Rosskopf, Judith Leitner, Gerhard J Zlabinger, et al.Cancer Immunology, Immunotherapy : CII|March 26, 2017
The multi-faceted potential of CD38 antibody targeting in multiple myelomaRory M Shallis, Christopher M Terry, Seah H LimCancer Immunology, Immunotherapy : CII|November 2, 2018
Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapyLaura A Vitale, Lawrence J Thomas, Li-Zhen He, et al.Cancer Immunology, Immunotherapy : CII|November 11, 2018
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinomaCharlotte M Huijts, Inge M Werter, Sinéad M Lougheed, et al.Cancer Immunology, Immunotherapy : CII|August 30, 2019
An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activationLuciano Castiello, Alessandra Zevini, Elisabetta Vulpis, et al.Cancer Immunology, Immunotherapy : CII|September 19, 2019
Induction of tumor-specific CD8+ cytotoxic T lymphocytes from naïve human T cells by using Mycobacterium-derived mycolic acid and lipoarabinomannan-stimulated dendritic cellsYuji Tomita, Eri Watanabe, Masumi Shimizu, et al.Cancer Immunology, Immunotherapy : CII|September 28, 2019
Activation of dendritic cells by targeted DNA: a potential addition to the armamentarium for anti-cancer immunotherapyMarlene Fyrstenberg Laursen, Emil Kofod-Olsen, Ralf AggerPageof 652